摘要
目的探讨眠安宁颗粒治疗失眠症的有效性及安全性。方法 149例失眠症患者随机分为眠安宁颗粒组(75例)和艾司唑仑组(74例)进行对照研究。以匹兹堡睡眠质量指数问卷(PSQI)、抑郁自评量表(SDS)、焦虑自评量表(SAS)、Asberg抗抑郁剂不良反应量表及临床观察评定疗效和不良反应。结果治疗第1周艾司唑仑组优于眠安宁颗粒组,第2周两种药物疗效基本相当,眠安宁组PSQI总分及各成分分明显下降(P<0.05),PSQI总分的减分率为59.21%,接近睡眠质量良好的PSQI指标(≤4分)。第3周末停药实验,艾司唑仑组反跳性失眠、日间困倦、头晕乏力等不良反应明显高于眠安宁颗粒组。结论眠安宁颗粒对于失眠症有效,且无明显不良反应、无依赖性。
Objective To investigate the efficacy and safety of Mian-an-ning granule in patients with insomnia. Methods 149 patients with insomnia were randomly divided into Mian-an-ning granule group （75 patients） and estazolam group （74 patients）. The efficacy and adverse reactions were evaluated using Pittsburgh Sleep Quality Index （PSQI）, SDS, SAS, Asberg antidepressant side effect scale and clinical observation results. Results The efficacy of estazolam group was superior to Mian-awning granule group after the first week of treatment, and was basically equal after the second week. Both treatments were stopped at the third week,and the adverse reactions of rebound insomnia, daytime sleepiness, dizziness and fatigue in estazolam group were apparently more than Mian-an-ning granule group. Conclusion The efficacy of Mian-an-ning granule in patients with insomnia was confirmed to be positive and there were no apparent adverse reactions and dependency.
出处
《重庆医学》
CAS
CSCD
北大核心
2013年第5期513-514,517,共3页
Chongqing medicine
关键词
入睡和睡眠障碍
眠安宁颗粒
艾司唑仑
sleep initiation and maintenance disorders
Mian-an-ning granule
estazolam
